Cargando…
Abstract 52: Clinical efficacy of dapagliflozin in patients with newly diagnosed type 2 diabetes
Background: The world is facing epidemic of diabesity (diabetes and obesity). Treating both the conditions can be difficult. There are limited available medicines that can treat both diabetes and obesity. Dapagliflozin (SGLT2 Inhibitor) is one such drug which can decrease body weight and obesity in...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067759/ http://dx.doi.org/10.4103/2230-8210.342169 |